X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/03/18/2847865/0/en/Scilex-Holding-Company-Provides-Responses-to-Product-Composition-Questions-Related-to-its-ELYXYB-Patent-in-Canada-for-a-New-Drug-Submission-Under-Review-by-Health-Canada-for-the-Ap.html
https://www.globenewswire.com//news-release/2024/01/18/2811519/37414/en/Panbela-Announces-Publication-of-Clinical-Data-Titled-Phase-1-study-of-high-dose-DFMO-celecoxib-cyclophosphamide-and-topotecan-for-patients-with-relapsed-neuroblastoma-A-New-Approa.html
https://www.globenewswire.com/news-release/2023/12/26/2801113/0/en/Scilex-Holding-Company-Announces-Filing-of-a-New-Drug-Submission-NDS-to-Health-Canada-s-Pharmaceutical-Drugs-Directorate-Bureau-of-Cardiology-Allergy-and-Neurological-Sciences-for-.html
https://www.globenewswire.com/news-release/2023/07/17/2705493/0/en/Virios-Therapeutics-Announces-Positive-Data-Demonstrating-Improvement-in-Multiple-Long-COVID-Symptoms-Following-Treatment-with-a-Combination-of-Valacyclovir-and-Celecoxib-in-an-Exp.html
https://www.globenewswire.com/news-release/2023/02/12/2606303/0/en/Scilex-Holding-Company-a-majority-owned-subsidiary-of-Sorrento-Therapeutics-Inc-acquires-rights-to-FDA-Approved-ELYXYB-in-the-U-S-and-Canada-for-the-acute-treatment-of-migraine.html
https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/
https://www.globenewswire.com/news-release/2021/09/09/2294359/0/en/BioDelivery-Sciences-International-Completes-Acquisition-of-ELYXYB-for-Acute-Migraine-Treatment-in-the-U-S-and-Canada.html
https://www.biospace.com/article/releases/virios-therapeutics-granted-new-patent-for-antiviral-inhibitor-combination-/?s=71
https://www.newswire.ca/news-releases/labelling-update-regarding-the-use-of-non-steroidal-anti-inflammatory-drugs-nsaids-beyond-20-weeks-of-pregnancy-and-risk-of-kidney-damage-to-unborn-babies-866562162.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213301
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213301
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-consensi-210045-amlodipine-besylate-and-celecoxibtablets-1597494563.pdf
https://www.newswise.com/coronavirus/two-anti-inflammatory-drugs-found-that-inhibit-the-replication-of-the-covid-19-virus/?article_id=732201
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213598
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211412
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208701
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208856
https://www.businesswire.com/news/home/20190430005302/en/Merck-Announces-First-Quarter-2019-Financial-Results/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.fool.com/investing/2018/03/14/is-gilead-sciences-trying-to-put-itself-out-of-bus.aspx
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-28-2018-1519803579.pdf
https://www.fiercepharma.com/marketing/what-s-beyond-hepatitis-c-drug-launch-hit-parade-ibrance-and-tecfidera-for-two
https://www.reuters.com/article/us-health-nsaids-overdosing/many-people-take-dangerously-high-amounts-of-ibuprofen-idUSKBN1FS336
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210071
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207061
http://www.pharmatimes.com/news/study_links_nsaids_with_higher_risk_of_cardiac_arrest_1189035
http://www.wsj.com/articles/study-suggests-celebrex-isnt-riskier-than-rival-pain-drugs-1479073501
http://www.reuters.com/article/us-health-nsaids-heart-failure-idUSKCN12K2J1
https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf
http://www.drugregulations.org/2016/08/ten-generic-drugs-to-be-withdrawn-in-uk.html
http://www.fiercepharma.com/pharma/pfizer-s-bextra-settlement-tagged-at-486m
http://www.biospace.com/News/pfizer-to-fork-over-486-million-to-settle-lawsuit/428174/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.fiercepharma.com/pharma/pfizer-agrees-to-settle-shareholder-class-action-celebrex-and-bextra
http://www.pharma-excipients.ch/2016/04/15/combination-of-solvent-displacement-and-wet-ball-milling-techniques-for-size-reduction-of-celecoxib/
http://www.reuters.com/article/us-pfizer-lawsuit-idUSKCN0X91SF
http://www.forbes.com/sites/ritarubin/2016/03/18/tylenol-not-effective-for-arthritis-pain-study-concludes-and-other-drugs-arent-exactly-winners/#469b8b4517c8
http://www.fiercebiotech.com/story/google-backs-cambridge-epigenetic-spin-21m-round/2016-03-14
http://www.business-standard.com/article/opinion/rebound-in-us-sales-a-big-positive-for-lupin-116020500981_1.html
http://www.business-standard.com/article/companies/aurobindo-gets-usfda-final-nod-for-isosulfan-injection-116020300299_1.html
http://www.business-standard.com/article/pti-stories/aurobindo-gets-usfda-nod-for-epilepsy-arthritis-drugs-116020200460_1.html
http://www.biospace.com/News/analysts-take-a-peek-at-pfizers-2015-drug-sales/404017/source=TopBreaking
http://www.prnewswire.com/news-releases/meta-analysis-of-54-studies-supports-use-of-glucosamine-and-chondroitin-as-combination-therapy-for-knee-osteoarthritis-oa-300195429.html
Market Place
Share 
